Esperion Therapeutics, Inc. Revenue Breakdown – LS:A1W1SJ
Esperion Therapeutics, Inc. (A1W1SJ) reported total revenue of €343.24 million last year, primarily from its "Patients with Elevated Low-density Lipoprotein Cholesterol" segment. The United States was the company's largest contributor to revenue, generating €343.24 million in the last fiscal year. This marks an increase from the previous year's total revenue of €321.01 million.
Vanguard Capital Management (ESPR) reports 13.1M-share, 5.08% stake in Esperion
Vanguard Capital Management has reported a 5.08% stake in Esperion Therapeutics Inc. (ESPR), amounting to 13,105,104 shares. The filing indicates Vanguard has sole voting power over 1,677,667 shares and sole dispositive power over all 13,105,104 shares, with no shared control. This position is held across various Vanguard investment companies and managed accounts, and no single person's interest within this holding exceeds 5%.
Esperion Therapeutics Inc (ESPR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article from TradingKey provides a revenue breakdown for Esperion Therapeutics Inc (ESPR). It states that relevant data regarding business segments, regional revenue, and profit contribution have not been disclosed by the company yet. The article includes current stock information for ESPR.
Esperion Therapeutics Inc (ESPR) Dividends & Stock Splits: Historical Payouts and Event Timeline
The article provides an overview of Esperion Therapeutics Inc (ESPR) focusing on its dividends and stock splits. It states that no dividends have been distributed over the past five years. The current stock price is $3.180, and the company has an 819.46M Market Cap.
Esperion Therapeutics Inc (ESPR) Cash Flow
This article provides a detailed cash flow statement for Esperion Therapeutics Inc (ESPR), showing quarterly and annual data for operating, investing, and financing activities. It includes definitions for various cash flow metrics and highlights the company's operating cash flow for fiscal 2025 at -13.09M, marking a 44.65% increase year-over-year. The free cash flow for the latest quarter was also -13.09M, reflecting a 45.38% change from the previous year.
ESPR|Esperion Therapeutics Inc|Price:3.180|
This article provides a detailed financial overview of Esperion Therapeutics Inc. (ESPR), including its stock price, market capitalization, and key financial statements such as the income statement, balance sheet, and cash flow statement. It highlights the company's latest earnings report, upcoming earnings date, and analyst rating, along with historical quarterly and annual financial indicators. The content also addresses frequently asked questions regarding the company's financial metrics.
Esperion Therapeutics, Inc. Revenue Breakdown – LSX:A1W1SJ
Esperion Therapeutics, Inc. (LSX:A1W1SJ) generated 343.24 million EUR last year, primarily from its "Patients with Elevated Low-density Lipoprotein Cholesterol" segment. This represents an increase from 321.01 million EUR in the previous year. The United States was the company's largest contributor to revenue.
Esperion Therapeutics, Inc. SEC Filing (Jul 23, 2026)
Esperion Therapeutics, Inc. (ESPR) filed a Form 15 with the SEC on July 23, 2026, to terminate its registration under Section 12(g) of the Securities Exchange Act of 1934 and suspend its duty to file reports. The filing indicates the company is relying on Rule 12g-4(a)(1) and Rule 12h-3(b)(1)(i) for this termination, noting only one holder of record as of the certification date. The certification was signed by Sheldon L. Koenig, President and CEO.
Akin Advises Pharmakon Advisors on Debt Financing for ARCHIMED’s Up to $1.1 Billion Acquisition of Esperion Therapeutics
Akin, an elite global law firm, advised Pharmakon Advisors, LP, and its BioPharma Credit funds on a unitranche debt facility. This financing will support ARCHIMED's acquisition of Esperion Therapeutics, Inc., a biopharmaceutical company specializing in cardiometabolic and rare/orphan disease therapies. The transaction is valued at up to approximately $1.1 billion and involved a large team of Akin attorneys.
[EFFECT] Esperion Therapeutics, Inc. SEC Filing
Esperion Therapeutics, Inc. (ESPR) filed an EFFECT form with the SEC, which was accepted on July 16, 2026, and became effective on July 15, 2026. The filing indicates a "Neutral" impact and sentiment. This SEC filing details the company's accession number, submission type, CIK, file number, and points to the original filing on SEC EDGAR.
Wasatch Advisors reports 0.7% Esperion Therapeutics (ESPR) stake
Wasatch Advisors has reported a 0.7% beneficial ownership stake in Esperion Therapeutics (ESPR), amounting to 1,930,185 shares. This filing, a Schedule 13G/A, indicates that Wasatch Advisors holds sole voting and dispositive power over these shares, qualifying it as an "Ownership of 5% or less of a class" investor. The firm's principal business office is located in Salt Lake City, and the shares are of the COM class with CUSIP 29664W105.
Esperion Therapeutics, Inc. SEC Filing (Jul 16, 2026)
This article reports on an SEC filing by Esperion Therapeutics, Inc. (ESPR) on July 16, 2026, which is an "EFFECT" type filing. The filing indicates the effectiveness of a previous submission with the SEC, dated July 15, 2026. The article also provides recent news and other SEC filings related to Esperion Therapeutics.
Enterprise value to revenue forward of Esperion Therapeutics, Inc. – DUS:0ET
This article provides financial information for Esperion Therapeutics, Inc. (DUS:0ET) on TradingView, focusing specifically on its enterprise value to revenue forward metric. The content highlights a specific financial period, value, and change for the company, accessible through the platform's financial and market data sections.
PFE6265887 Bond Risk Profile
This page provides a risk profile for the Esperion Therapeutics, Inc. bond (PFE6265887) with a 5.75% coupon maturing on June 15, 2030. It highlights key metrics for credit risk assessment, including security level, inflation protection, and issuer rating, to help users evaluate the bond's reliability. The platform, TradingView, offers an in-depth breakdown and access to analyst ratings.
Form 4 Esperion Therapeutics Inc For: 13 July By Investing.com
This article announces the filing of Form 4 for Esperion Therapeutics Inc., dated July 13. Form 4 is a document filed with the SEC by company insiders detailing changes in their ownership of the company's stock. The article mentions the stock symbol ESPR and its slight price change.
PFE6265887 Bond Profile — Key Metrics
This article provides key metrics for the Esperion Therapeutics, Inc. bond PFE6265887, which has a 5.75% coupon rate and matures on June 15, 2030. The bond has an outstanding amount of $100 million and a face value of $1,000. Esperion Therapeutics is a biopharmaceutical company focused on therapies for elevated low-density lipoprotein cholesterol.
[Form 4] Esperion Therapeutics, Inc. Insider Trading Activity
Esperion Therapeutics' CFO Benjamin Halladay disposed of his equity, including 705,410 shares of common stock and various stock options, due to the company's merger with Essence Parent Inc. The merger converted each share of common stock and in-the-money options into $3.16 cash plus one contingent value right per share. Halladay no longer holds any shares or stock options in Esperion Therapeutics after these transactions.
Esperion Therapeutics (ESPR) director equity cashed out at $3.16 plus CVRs in merger
Esperion Therapeutics director Seth H. Z. Fischer cashed out his equity holdings in the company as part of a merger where Esperion became a wholly-owned subsidiary of Essence Parent Inc. He disposed of 141,023 common shares, 79,873 restricted stock units, and several in-the-money stock options, all converted into $3.16 cash per share plus one contingent value right (CVR) for potential future payments based on milestones. Following these transactions, Fischer holds no direct Esperion common stock or the reported options.
Esperion Therapeutics (ESPR) director converts shares and options into $3.16 cash and CVRs
Esperion Therapeutics director Jay Shepard reported dispositions of shares and stock options following the closing of a merger with Essence Parent Inc. and Essence MergerCo Inc. His 164,472 common shares were converted into $3.16 cash per share plus one contingent value right (CVR) per share. Additionally, 97,500 "in-the-money" stock options were converted into cash (equaling $3.16 minus the exercise price) and one CVR per underlying share.
Esperion Therapeutics (ESPR) director equity cashed out at $3.16 plus CVRs
Esperion Therapeutics director Robert E. Hoffman reported the disposition of common stock and stock options due to the company's merger, where it became a wholly owned subsidiary of Essence Parent Inc. His 85,153 shares were converted into $3.16 cash per share plus one
[POSASR] Esperion Therapeutics, Inc. SEC Filing
Esperion Therapeutics, Inc. has filed a Post-Effective Amendment No. 1 to its Form S-3ASR registration statement (No. 333-258397) to deregister unsold securities. This action follows the company's merger with Essence MergerCo Inc., a wholly-owned subsidiary of Essence Parent Inc., which became effective on July 13, 2026. As a result of the merger, Esperion Therapeutics has terminated all offerings of its securities registered under existing registration statements.
[POS AM] Esperion Therapeutics, Inc. SEC Filing
Esperion Therapeutics, Inc. has filed a post-effective amendment to several S-3 and S-3MEF registration statements to deregister unsold securities. This action follows the company's merger with MergerCo, a wholly-owned subsidiary of Essence Parent Inc., which became effective on July 13, 2026. As a result of the merger, Esperion has terminated all offerings of its securities under these existing registration statements.
Esperion Therapeutics Announced Transfer or Voluntary Withdrawal of Listing
Esperion Therapeutics (ESPR) announced its decision to delist its common stock from Nasdaq following a merger. The company has requested Nasdaq to file a Form 25 for delisting and deregistration and plans to file a Form 15 to suspend its SEC reporting obligations.
Esperion Therapeutics (ESPR) moves to remove its Nasdaq listing
Esperion Therapeutics, Inc. (ESPR) is removing its common stock from listing and registration on the Nasdaq Stock Market LLC under Section 12(b) of the Securities Exchange Act of 1934. This delisting was certified by Nasdaq and affects the company's common stock, meaning less visibility and potentially lower trading volume for investors. The filing complies with relevant SEC rules for voluntary withdrawal from listing.
Esperion Therapeutics, Inc.(NasdaqGM:ESPR) dropped from Russell 2000 Value-Dynamic Index
Esperion Therapeutics, Inc. (NasdaqGM:ESPR) has been dropped from the Russell 2000 Value-Dynamic Index. This article also details the company's profile as a commercial-stage biopharmaceutical company focused on cardiometabolic and rare/orphan disease therapies, including its products NEXLETOL, NEXLIZET, NILEMDO, and NUSTENDI. The company's current stock performance, analyst consensus, and various quality and ESG ratings are also provided.
Esperion Therapeutics, Inc.(NasdaqGM:ESPR) dropped from Russell 3000 Value Benchmark
Esperion Therapeutics, Inc. (NasdaqGM:ESPR) has been removed from the Russell 3000 Value Benchmark, alongside several other Russell indices. The biopharmaceutical company specializes in developing cardiometabolic and rare/orphan disease therapies, including medications like NEXLETOL and NEXLIZET for managing LDL-C levels. The company's stock, listed on NasdaqGM, was trading at 3.180 USD, down 0.31% on July 9, 2026.
Esperion Therapeutics Clears Key Hurdle as Stockholders Approve Essence Merger
Esperion Therapeutics' stockholders have approved the company's merger agreement with Essence Parent and Essence MergerCo in a virtual meeting held on July 8, 2026. The approval means Essence MergerCo will merge with Esperion, with Esperion becoming a wholly-owned subsidiary of Essence Parent. Stockholders also approved an advisory proposal for executive compensation related to the merger, while a proposal for meeting adjournment was not needed due to the primary merger approval.
Esperion Therapeutics Clears Key Hurdle as Stockholders Approve Essence Merger
Stockholders of Esperion Therapeutics (ESPR) approved the company’s merger agreement with Essence Parent and Essence MergerCo at a special meeting on July 8, 2026. The approval includes a non-binding advisory vote on executive compensation related to the transaction. Final voting results will be filed with the SEC in a Form 8-K.
Esperion Therapeutics Clears Key Hurdle as Stockholders Approve Essence Merger
Esperion Therapeutics stockholders have approved the company's merger agreement with Essence Parent and Essence MergerCo at a special virtual meeting held on July 8, 2026. Under the terms of the deal, Esperion will become a wholly-owned subsidiary of Essence Parent. Stockholders also advisedly approved potential compensation for Esperion's named executive officers related to the merger.
Esperion Therapeutics, Inc.(NasdaqGM:ESPR) dropped from Russell Small Cap Comp Value Index
Esperion Therapeutics, Inc. (NasdaqGM:ESPR) has been removed from the Russell Small Cap Comp Value Index, as well as several other Russell indices including the Russell 2000 Growth, Russell 2500 Growth, and Russell 3000 indices. The company is a biopharmaceutical firm focused on cardiometabolic and rare/orphan disease therapies, offering products like NEXLETOL and NEXLIZET for cholesterol management.
Esperion Therapeutics, Inc.(NasdaqGM:ESPR) dropped from Russell 2000 Growth Benchmark
Esperion Therapeutics Inc. (NasdaqGM:ESPR) has been removed from several Russell Growth and Value benchmarks, including the Russell 2000 Growth Benchmark. This move affects the company's inclusion in various small-cap and broader Russell indices. Esperion Therapeutics is a biopharmaceutical company focused on cardiometabolic and rare/orphan disease therapies, offering products like NEXLETOL and NEXLIZET.
Esperion Therapeutics (ESPR) investors back merger with Essence Parent in special meeting vote
Esperion Therapeutics (ESPR) stockholders have approved the merger with Essence Parent Inc. at a special meeting held on July 8, 2026. This approval, with 135,326,793 votes in favor, moves forward the transaction for Esperion to become a wholly owned subsidiary of Essence Parent. The company noted that while the merger proposal passed, it remains subject to various closing conditions and risks, including potential termination events and the uncertainty of contingent value right payments.
Esperion Therapeutics stock leans on its cholesterol portfolio.
Esperion Therapeutics, a Nasdaq-listed company, is judged by the market on the performance of its cholesterol-lowering medicines, commercial execution, and prescription trends. The company's core business focuses on non-statin LDL-C lowering therapies, Nexletol and Nexlizet. Success hinges on physician adoption and payer access in a competitive cardiovascular care market, with current information suggesting the stock's story relies on its product base rather than new market catalysts.
Esperion Therapeutics (ESPR) AGM 2026 Summary
Esperion Therapeutics held its 2026 AGM, marking the CEO's sixth year and confirming a quorum with over 257 million shares. Two Class I directors were nominated for re-election, and shareholders approved all four proposals, including the election of directors, executive compensation, auditor ratification, and a stock option plan amendment. The article also notes recent events such as acquisition announcements and merger votes, indicating significant corporate activity for Esperion.
Esperion Therapeutics (ESPR) Stock Forecast & Analyst Ratings
This article provides a stock forecast and analyst ratings for Esperion Therapeutics (ESPR). It includes detailed financial analysis, price targets from various analysts, and a summary of recent performance and market sentiment for the company.
ESPR - Esperion Therapeutics Inc Volatility & Greeks
This article provides a detailed financial overview of Esperion Therapeutics Inc (ESPR), including its stock performance, market capitalization, income, sales, and various financial ratios. It also lists insider and institutional ownership, short interest, and volatility metrics, alongside analyst recommendations and target prices. The data aims to offer a comprehensive snapshot of the company's financial health and market position.
Esperion Therapeutics focuses on cholesterol treatments as investors watch long-term growth
Esperion Therapeutics, a biopharmaceutical company, centers its strategy on developing oral non-statin cholesterol therapies for patients who cannot tolerate statins or need additional lipid-lowering support. The company aims to differentiate itself by offering an oral alternative in a market dominated by statins and injectable therapies, focusing on treatments that reduce LDL-C and cardiovascular events. Investors are watching the company's ability to secure regulatory approvals, navigate market competition, and expand patient adoption, with stock performance reflecting its success in translating scientific expertise into commercial traction.
10 Health Care Stocks With Whale Alerts In Today’s Session
This article identifies 10 healthcare stocks that showed "whale alerts" in their options trading activity during today's session, indicating significant movements by large-volume traders. It details specific call and put options with varying sentiments (bearish, bullish, neutral) for companies like Esperion Therapeutics, Revolution Medicines, and Tenet Healthcare, providing strike prices, expiration dates, and total trade prices. The alerts are based on options activity that diverges from normal worth, suggesting potential trading opportunities.
Enterprise value to revenue forward of Esperion Therapeutics, Inc. – NASDAQ:ESPR
This article provides financial information for Esperion Therapeutics, Inc. (ESPR) on TradingView, focusing on its enterprise value to forward revenue. It highlights the company's stock market presence on Nasdaq within the pharmaceuticals sector, offering an overview of its financials and market data.
Price to earnings forward of Esperion Therapeutics, Inc. – NASDAQ:ESPR
The article focuses on the "Price to earnings forward" metric for Esperion Therapeutics, Inc. (NASDAQ: ESPR). It briefly presents this specific financial data point within a larger financial platform context, implying it's a key piece of information for investors. However, no actual financial figures are provided in the content.
Esperion Therapeutics, Inc. Actuals & Estimates (DUS:0ET)
This article provides an overview of Esperion Therapeutics, Inc. (0ET) on the Dusseldorf Stock Exchange, including its financial actuals and analyst estimates. It covers key financial metrics like earnings, revenue, net income, and EBITDA, as well as stock performance data and an upcoming earnings release date. The article also addresses frequently asked questions regarding the company's stock ticker, future price forecasts, historical highs and lows, and dividend policy.
Esperion Therapeutics Inc (ESPR) Institutional Confidence
Esperion Therapeutics Inc (ESPR) has an institutional shareholding score of 5.00, ranking 73rd out of 157 in the Pharmaceuticals industry. Institutional shareholding has increased by 2.95% quarter-over-quarter, now standing at 66.50%. Chuck Royce is the largest institutional shareholder, holding 2.30M shares, representing 1.02% of shares outstanding.
Esperion Therapeutics (ESPR) Stock Fair Value Moves Lower After Analyst Downgrades
Esperion Therapeutics (ESPR) has seen its fair value estimate significantly downgraded by analysts, moving from approximately US$6.50 to US$3.19 per share, a 51% reduction. This adjustment reflects a more cautious stance from several investment firms regarding the company's execution on growth plans and potential revenue. The revised targets incorporate changes in revenue growth assumptions, net profit margin forecasts, and future P/E multiples, indicating a tighter valuation framework for the company.
Esperion Therapeutics (ESPR) Proxy filing Summary
Esperion Therapeutics (ESPR) has entered a definitive agreement to be acquired by ARCHIMED for $3.16 per share in cash, with potential milestone payments up to $100 million. The transaction is expected to close in Q3 2026, pending regulatory and shareholder approval. Shareholders will vote on the merger, which the Board recommends approving.
Esperion (ESPR) CEO sells shares to cover RSU taxes, retains 2.12M
Esperion Therapeutics, Inc. President and CEO Sheldon L. Koenig sold 53,588 shares of common stock at $3.155 per share. This transaction was conducted to satisfy tax obligations related to vested restricted stock units, a common practice in equity compensation. Following the sale, Koenig retains a substantial direct holding of 2,119,111 shares, indicating the sale was for tax purposes rather than a reduction in his overall confidence in the company.
Esperion (NASDAQ: ESPR) CFO sells shares to pay taxes on vested RSUs
Esperion Therapeutics' CFO, Benjamin Halladay, sold 10,773 shares of common stock at $3.155 per share to cover tax obligations from vested restricted stock units. This transaction, filed on a Form 4, indicates a net sale of $33,989 but Halladay still retains a substantial direct holding of 702,829 shares in the company. Such sales are described as routine tax-related events rather than discretionary portfolio decisions.
Esperion (NASDAQ: ESPR) details Corstasis acquisition cost, debt and royalty financing
Esperion Therapeutics (NASDAQ: ESPR) has filed an amended 8-K report detailing the financial aspects of its acquisition of Corstasis Therapeutics, which closed on April 2, 2026. The acquisition, treated as an asset acquisition, cost $83.389 million, primarily allocated to the acquired product Enbumyst, and was funded by a $25.0 million term loan and a $50.0 million royalty sale. Pro forma financials for 2025 show that the acquisition widened Esperion's net loss from $22.682 million to $47.063 million, primarily due to amortization and increased financing costs.
Esperion (NASDAQ: ESPR) CLO trims 11,824 shares to pay RSU taxes
Esperion Therapeutics' Chief Legal Officer, Benjamin Looker, sold 11,824 shares of common stock at an average price of $3.155 per share. This transaction was conducted to cover tax obligations arising from recently vested restricted stock units (RSUs). Following the sale, Mr. Looker still retains a direct holding of 667,524 shares in the company.
ESPR insider sale notice: 53,588 shares tied to vesting (ESPR)
Esperion Therapeutics (ESPR) filed a Form 144 notice indicating 53,588 shares of common stock are listed for sale, tied to restricted stock vesting on June 16, 2026, and designated as compensation. This filing enables the resale of these shares under Section 144 procedures. The notice also reveals a prior sale of 25,578 shares on March 17, 2026, for $69,551.70 by Sheldon Koenig.
Esperion Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Esperion Therapeutics, Inc. - ESPR
Kahn Swick & Foti, LLC (KSF) is investigating the proposed sale of Esperion Therapeutics, Inc. (NasdaqGM: ESPR) to ARCHIMED-managed funds. The law firm is evaluating whether the consideration of $3.16 cash per share plus contingent milestone payments is adequate and whether the process leading to the proposed sale was fair to shareholders. KSF encourages shareholders who believe the transaction undervalues the company to contact them.
